Baidu
map

Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study

Joerger, M; Hundsberger, T; Haefliger, S; von Moos, R; Hottinger, AF; Kaindl, T; Engelhardt, M; Marszewska, M; Lane, H; Roth, P; Stathis, A

Kaindl, T (通讯作者),Basilea Pharmaceut Int Ltd, Hegenheimermattweg 167b, CH-4123 Allschwil, Switzerland.

INVESTIGATIONAL NEW DRUGS, 2023; 41 (2): 267

Baidu
map
Baidu
map
Baidu
map